[:pt]APTAH is a Brazilian Bioinformatics company specializing in Drug Design[:]


Alzheimer’s Disease​

Crowfounding Campaign

Alzheimer’s disease, a type of dementia, is an irreversible, progressive brain disease that affects an estimated 5.7 million Americans. It is the sixth leading cause of death among all adults and the fifth leading cause for those aged 65 or older. It is the cause of 60–70% of cases of dementia. The most common early symptom is memory loss. The typical life expectancy following diagnosis is three to nine years. No treatments stop or reverse its progression. In developed countries, Alzheimer’s disease is one of the most financially costly diseases.

In 2018, it’s estimated that more than 16 million Americans are providing more than 18.4 billion hours of unpaid care for family and friends with Alzheimer’s and other dementia. In 2017, total payments for health care, long-term care, and hospice for people with Alzheimer’s and other dementia are estimated to be $259 billion. Unless scientists discover how to prevent or treat Alzheimer’s, the number of people and the care costs will increase substantially.

Aptah Biotechnology is an innovative biotechnology startup working on the development of new medicine to control the progression of Alzheimer’s disease helping, in the long term, all people that suffer from this terrible unstoppable disease. We are asking for help in starting preclinical trials on our new medicine. Depending on how the results, we intend to release a laboratory test kit to accurately diagnose Alzheimer’s disease in its early stages. In the long term we intend to act as reference in Alzheimer’s diagnosis and eventually find a cure for Alzheimer’s disease. Every step we take will be updated on this website and on our social media. The tests will start during the third quarter of this year in a multicentric third part laboratory structure.

With your help we will be able to make important advances in preclinical and clinical trials including but not limited to docking tests, affinity tests, internalization tests, protein expression tests and TAU modulation tests, and clinical trials phase I. We will follow the Good Laboratory Practice and Good Clinical Practice to align our research with the requirements of regulatory agencies requirements.

pt_BR en_US